Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.

Advertisement

Related Content

NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
Bristol/Pfizer's Apixaban Shows Mortality Benefit In ARISTOTLE, But Is It Enough To Supplant Warfarin?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS004878

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel